News and Trends 2 Sep 2022 Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the U.S. Food and Drug Administration (FDA) has approved the first treatment option, SPEVIGO, for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, […] September 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents. These are: one in India, and continuation patents in China, Australia and the U.S. This means the company’s method for using modified bacteria for treatment of both mucosal and cutaneous wounds in […] August 25, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2022 Treatment for patients with fragile skin disease accepted by FDA The U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for B-VEC, a treatment for patients with dystrophic epidermolysis bullosa (DEB). Krystal Biotech Inc. works in redosable gene therapy and made the announcement today (August 18). The application has been granted Priority Review designation, and the Prescription Drug […] August 19, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Almirall launches new call to find innovative therapies for skin diseases A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […] July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB). B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown? Two clinical studies have demonstrated the capacity of Novartis’ monoclonal antibody to treat both plaque and scalp psoriasis and improve patient quality of life. Not only is Novartis leading the CAR-T cell therapy field with the approval of Kymriah last year, the big pharma is also developing drugs for diseases affecting the immune system. The company presented […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia for the condition at the American Academy of Dermatology’s annual meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2017 Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe Following its FDA approval in July, MorphoSys’ anti-IL23 antibody has been approved to treat moderate-to-severe psoriasis by the European Commission. German biotech, MorphoSys, is a leader in the field of therapeutic antibodies for series diseases including cancer, arthritis and Alzheimer’s. Today, the company has announced that the licensee, Janssen, has received approval from the European Commission […] November 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2017 Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis Though the psoriasis market is teeming with effective products, companies have developed ways to devise new, more effective modes of treatment. Psoriasis is a common autoimmune disorder that affects the skin, often causing patches of dry, itchy, and painful lesions. In severe cases, people can develop psoriatic arthritis, which can lead to painful inflammation in […] October 17, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman Stetsyk /Shutterstock October 2, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 Update: After 25 years, MorphoSys Gets its First Antibody Approved Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […] September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […] July 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email